Jiedu Xiaozheng Yin Induces M1 Macrophage Polarization to Inhibit Colitis-Associated Colorectal Cancer Progression

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with colitis-associated colorectal cancer (CAC) presenting increased malignancy and therapeutic challenges compared to sporadic forms. The tumor microenvironment, particularly the phenotypic polarization of macrophages, is recognized as a crucial factor in CRC pathogenesis. Macrophages are functionally plastic, exhibiting either a pro-inflammatory M1 phenotype that suppresses tumor progression or an anti-inflammatory M2 phenotype that facilitates tumor growth and immune evasion. Traditional Chinese medicine (TCM), with its capacity to target multiple cellular pathways, has gained attention for modulating immune responses in cancer. Jiedu Xiaozheng Yin (JXY) is a TCM formulation with reported anti-tumor activities, yet its mechanistic role in regulating macrophage polarization in CAC was previously unclear. The research question addressed by Liu et al. is whether JXY inhibits CAC progression by driving macrophage polarization toward the M1 phenotype via Toll-like receptor 4 (TLR4) signaling.

Key Innovation from the Reference Study

The principal innovation of this study is the demonstration that JXY mediates its anti-tumor effects in CAC by specifically stimulating M1-type macrophage polarization through the TLR4 pathway. Unlike prior work that highlighted multi-pathway anti-cancer properties of JXY, Liu et al. elucidate a direct link between TCM-induced immune reprogramming and suppression of colon tumor development. This mechanistic insight advances the field by positioning innate immune modulation—not just direct tumor cytotoxicity—as a viable therapeutic axis in CAC, and provides a framework for further investigation of transcriptional coactivator disruption in tumor-associated macrophage biology.

Methods and Experimental Design Insights

The study employed both in vivo and in vitro approaches to dissect the immunomodulatory effects of JXY in CAC:

• Orthotopic CAC Mouse Model: Mice were induced to develop colitis-associated tumors, followed by JXY administration. Colon length, tumor count, and organ indices (liver, spleen, thymus) were systematically recorded.
• Histological and Immunohistochemical Analyses: Hematoxylin and eosin (H&E) staining assessed mucosal injury and tumor burden, while immunohistochemistry quantified M1 and M2 macrophage markers in colonic tissue.
• Cellular and Molecular Characterization: The RAW264.7 murine macrophage line was treated with JXY, and phenotypic markers of M1 (IL-1β, TNF-α, iNOS, CD80, CD86) and M2 (Arg-1, CD206, IL-10) polarization were measured using RT-qPCR and flow cytometry. Phagocytic function was also evaluated.
• Pathway Antagonism: To interrogate pathway specificity, antagonists for TLR4 (TAK242), NF-κB (PDTC), CREB (KG-501), AP-1 (SR11302), and PI3K (LY294002) were employed. Changes in pro-inflammatory gene expression (IL-6, TNF-α, iNOS, IL-1β) were determined following pathway inhibition.

Core Findings and Why They Matter

The data reveal several important outcomes. JXY administration significantly improved pathological indices in CAC mice, including longer colon length and reduced tumor number. Histological examination confirmed attenuated mucosal injury and tumor formation. Immunohistochemistry demonstrated a marked increase in M1 macrophage markers with concomitant reduction in M2 markers, indicating a shift towards a pro-inflammatory, tumor-suppressive microenvironment. In vitro, JXY treatment upregulated M1-associated molecules and enhanced macrophage phagocytic function, while downregulating M2 markers.

Notably, when the TLR4 pathway was pharmacologically antagonized, the ability of JXY to induce M1 polarization and pro-inflammatory gene expression was significantly diminished. This establishes TLR4 signaling as a pivotal mediator of JXY's immunomodulatory effects. Furthermore, the use of the selective CREB inhibitor KG-501 (3-((4-chlorophenyl)carbamoyl)naphthalen-2-yl dihydrogen phosphate) in these assays implicates CREB-mediated transcription in macrophage phenotype regulation and highlights the value of transcriptional coactivator disruption as a research tool in this context.

These findings are significant as they support the paradigm that manipulating macrophage polarization—specifically promoting M1 phenotype via innate immune receptors—can impede CAC progression. The study also underscores the broader role of transcriptional regulation, as agents like KG-501 function as epigenetic regulation modulators and oncogenic signaling pathway inhibitors.

Comparison with Existing Internal Articles

This study’s conclusions resonate with recent internal reviews on small-molecule transcription inhibitors. For example, "KG-501: Applied Workflows for Disrupting CREB-Mediated Transcription" highlights the utility of KG-501 in precisely disrupting CREB–KIX domain interactions, facilitating the study of immune modulation and cancer pathways. Similarly, "KG-501: Unlocking CREB-Myb Axis Disruption for Translational Oncology" positions KG-501 as an advanced tool for dissecting the CREB-Myb transcriptional axis in cancer and immunology workflows, aligning with the reference study’s use of transcriptional coactivator antagonists to probe macrophage functional states. The internal article "Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization in CAC via TLR4" offers further mechanistic commentary on the central findings, reinforcing the translational importance of targeting macrophage phenotypes in the tumor microenvironment.

Limitations and Transferability

Although the study robustly demonstrates JXY-induced M1 polarization and tumor suppression in a murine CAC model, several limitations should be considered. The translatability of murine findings to human CRC remains to be validated, particularly given interspecies differences in immune cell composition and TCM pharmacodynamics. The study’s focus on acute-phase responses and use of a single cell line (RAW264.7) may not capture the heterogeneity of macrophage states in human tumors. Additionally, while the involvement of the TLR4 pathway is compelling, the precise downstream transcriptional networks—beyond the tested coactivators—require further elucidation. The use of pharmacological inhibitors like KG-501 provides mechanistic insight but may not fully recapitulate genetic or clinical settings. Finally, the multi-component nature of JXY complicates attribution of effects to individual constituents, and the potential for off-target actions or systemic immunomodulation warrants further exploration.

Protocol Parameters

• JXY administration in vivo: Dosage and timing as per Liu et al.; typically administered daily post-CAC induction, with monitoring of clinical and histopathological endpoints.
• Macrophage phenotype assessment: Use RT-qPCR and flow cytometry to quantify M1 (IL-1β, TNF-α, iNOS, CD80, CD86) and M2 (Arg-1, CD206, IL-10) markers following treatment.
• Pathway antagonism (e.g., CREB inhibition): Apply KG-501 at concentrations consistent with its reported IC50 for CREB inhibition (6.89 μM) according to the product information, using DMSO as solvent, and assess downstream gene expression changes after 24–48 hours.
• TLR4 pathway antagonism: Employ TAK242 or comparable inhibitors to dissect pathway specificity in vitro, with appropriate vehicle controls.
• Phagocytic function assays: Measure macrophage uptake of fluorescent beads or labeled bioparticles following JXY or antagonist treatment to confirm functional polarization.

Research Support Resources

To facilitate studies of transcriptional regulation in macrophage polarization and tumor microenvironment research, investigators may employ KG-501 (SKU B8380), a well-characterized small-molecule CREB inhibitor within the naphthalene-2-carboxanilides family. KG-501 disrupts CREB–KIX domain interactions and has demonstrated efficacy as a transcriptional coactivator disruption tool in cell-based assays. Researchers interested in probing the roles of CREB and Myb in immune modulation, as highlighted by Liu et al., can integrate KG-501 into their experimental workflows, with product protocols and handling recommendations available from APExBIO.